Telomir Pharmaceuticals

epigenetics, metabolism, small molecules

modulatingsmall molecule

telomirpharma.com·Miami, Florida, United States·$1M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-6VCI

Projects

Telomir-Zn for advanced or metastatic triple-negative breast cancer

phase 1

drug program · high · Thu Oct 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Evaluate Telomir-Zn as an oral monotherapy for adults with advanced or metastatic triple-negative breast cancer, with goals including safety, tolerability, pharmacokinetics, pharmacodynamics, recommended Phase II dose, and preliminary antitumor activity.

First-in-human, multicenter, open-label Phase I/II clinical trial using a modified 3+3 dose-escalation design followed by a Simon two-stage Phase II expansion at the recommended Phase II dose.

Phase I/II clinical trial listed for oral Zn-Telomir monotherapy in advanced or metastatic TNBC.

Telomir-Zn for type 2 diabetes and insulin resistance

preclinical

research program · high

Investigate whether Telomir-Zn can restore glucose homeostasis, reduce insulin resistance, and improve metabolic dysfunction associated with type 2 diabetes.

Diet-induced zebrafish model of non-insulin-dependent diabetes mellitus treated with Telomir-Zn or Telomir-1 at three dose levels for 14 days, with metabolic outcomes including fasting glucose, oral glucose tolerance, fasting insulin, and HOMA-IR.

Publication reporting preclinical metabolic effects of Telomir-Zn in a diet-induced zebrafish model of type 2 diabetes.

Telomir-Zn produced dose-dependent reductions in fasting glucose, improved glucose clearance during OGTT, reduced fasting insulin, and lowered HOMA-IR values from approximately 10 to 12 in diabetic fish to approximately 3 in treated groups.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence